#1 Clinical Trials Search in Europe

Wt1 Mrna Dc

A new clinical trial is exploring the potential of a vaccine called WT1 mRNA DC to prevent relapse in adults with acute myeloid leukemia (AML). This innovative treatment uses dendritic cells, a type of immune cell, to target a specific protein called Wilms’ tumor 1 (WT1) that is often found in leukemia cells. The trial aims to determine if this vaccine can effectively boost the immune system’s ability to fight against remaining cancer cells and improve overall survival for AML patients.

Table of Contents

What is WT1 mRNA DC?

WT1 mRNA DC is an innovative vaccine being studied for the treatment of Acute Myeloid Leukemia (AML). This vaccine is a type of cell therapy, which means it uses cells from your own body to fight the disease.[1]

The full name of this treatment is “Wilms’ tumor (WT1) antigen-targeted dendritic cell vaccination.” Let’s break this down:

  • Wilms’ tumor (WT1): This refers to a specific protein found in many leukemia cells.
  • Dendritic cells: These are special immune cells that help your body recognize and fight off harmful substances.
  • Vaccination: Unlike traditional vaccines that prevent diseases, this is a therapeutic vaccine designed to treat an existing condition.

Target Condition: Acute Myeloid Leukemia

WT1 mRNA DC is being developed to treat Acute Myeloid Leukemia (AML). AML is a type of blood cancer that affects the bone marrow, where blood cells are made. In AML, abnormal white blood cells grow rapidly, interfering with the production of normal blood cells.[1]

How WT1 mRNA DC Works

The WT1 mRNA DC vaccine works by stimulating your immune system to fight leukemia cells. Here’s a simplified explanation of the process:

  1. Doctors collect some of your monocytes (a type of white blood cell).
  2. These monocytes are transformed into dendritic cells in a laboratory.
  3. The dendritic cells are then “loaded” with WT1 mRNA, which contains instructions for making the WT1 protein found on leukemia cells.
  4. When injected back into your body, these modified dendritic cells help your immune system recognize and attack leukemia cells that have the WT1 protein.

This approach is known as immunotherapy because it uses your own immune system to fight the cancer.[1]

Clinical Trial Details

WT1 mRNA DC is currently being studied in a Phase II clinical trial. This means that while it has shown promise in earlier studies, it is still considered experimental. The main goals of this trial are:

  • To see if the vaccine can prevent AML from coming back (relapse) after initial treatment.
  • To determine if it can help patients live longer overall.
  • To check if it can reduce or eliminate any remaining cancer cells after standard treatment (known as minimal residual disease).
  • To study how the vaccine affects patients’ immune systems and quality of life.[1]

Eligibility Criteria

Not all AML patients are eligible for this trial. Some key criteria include:

  • Being 18 years or older
  • Having a high risk of AML relapse
  • Having completed standard AML treatment and achieved remission
  • Not being eligible for or choosing not to have a stem cell transplant

There are also several factors that might exclude a patient from participating, such as having certain other medical conditions or being pregnant.[1]

Potential Benefits

While the effectiveness of WT1 mRNA DC is still being studied, researchers hope it may offer several benefits:

  • Preventing or delaying AML relapse
  • Improving overall survival
  • Eliminating remaining cancer cells after standard treatment
  • Enhancing quality of life for AML patients[1]

Administration and Treatment Duration

WT1 mRNA DC is given as an intradermal injection, which means it’s injected just under the skin. The treatment period can last up to 97 days (about 3 months). The exact dosing schedule and amount may vary based on individual patient factors and will be determined by the healthcare team.[1]

Aspect Details
Trial Type Phase II, multicenter, randomized, open-label
Main Objective Determine efficacy of WT1 mRNA DC vaccination to prevent relapse and prolong overall survival in AML patients
Target Population Adults (≥18 years) with AML at high risk of relapse
Treatment WT1 mRNA-electroporated dendritic cell vaccination
Administration Intradermal injection
Primary Endpoint Overall survival
Secondary Endpoints Relapse-free survival, relapse rate, minimal residual disease, immune responses, quality of life
Eligibility Completed specific chemotherapy regimens, achieved complete remission or CRi, good performance status
Exclusion Criteria Other malignancies, immunosuppressive diseases, use of immunosuppressive drugs, pregnancy

FAQ

  • What is WT1 mRNA DC vaccine? WT1 mRNA DC vaccine is a type of immunotherapy that uses dendritic cells (a type of immune cell) loaded with genetic material (mRNA) from the Wilms' tumor 1 (WT1) protein. This vaccine is designed to stimulate the immune system to recognize and attack leukemia cells that express the WT1 protein.
  • Who is eligible for this clinical trial? The trial is open to adults (18 years or older) with acute myeloid leukemia (AML) who are at high risk of relapse. Eligible patients must have completed specific chemotherapy treatments and achieved complete remission or complete remission with incomplete blood recovery. Patients must also have a good performance status and not be eligible for or willing to receive stem cell transplantation.
  • How is the vaccine administered? The WT1 mRNA DC vaccine is administered through intradermal injection, which means it is injected just beneath the skin. The exact dosing schedule and number of injections will be determined by the study protocol.
  • What are the main goals of this clinical trial? The primary goal is to determine if the WT1 mRNA DC vaccine can prevent relapse and improve overall survival in AML patients. Secondary goals include assessing relapse rates, monitoring minimal residual disease, evaluating immune responses, and measuring the impact on patients' quality of life.
  • Are there any side effects associated with the WT1 mRNA DC vaccine? While specific side effects for this vaccine are not mentioned in the trial information, immunotherapies can sometimes cause immune-related side effects. The trial will closely monitor patients for any adverse reactions. It's important to note that the safety profile will be thoroughly evaluated as part of the study.

Ongoing Clinical Trials on Wt1 Mrna Dc

  • Study on WT1 mRNA DC Vaccine to Prevent Relapse in Adults with Acute Myeloid Leukemia

    Not recruiting

    2 1 1
    Investigated drugs:
    Belgium

Glossary

  • Acute Myeloid Leukemia (AML): A type of blood cancer that affects the bone marrow and blood, characterized by rapid growth of abnormal white blood cells that interfere with normal blood cell production.
  • Dendritic Cells (DC): Specialized immune cells that help the body recognize and fight foreign substances, including cancer cells. In this vaccine, they are used to present the WT1 protein to the immune system.
  • Wilms' Tumor 1 (WT1): A protein often found in higher levels in leukemia cells. The vaccine targets this protein to help the immune system recognize and attack cancer cells.
  • mRNA: Messenger RNA, a type of genetic material that carries instructions for making proteins. In this vaccine, mRNA for the WT1 protein is used to 'teach' the immune system to recognize leukemia cells.
  • Remission: A state in which cancer symptoms are reduced or disappear. Complete remission (CR) means no detectable cancer, while complete remission with incomplete blood recovery (CRi) means no detectable cancer but blood cell counts haven't fully recovered.
  • Minimal Residual Disease (MRD): Small numbers of cancer cells that remain in the body after treatment, often undetectable by standard tests. Monitoring MRD helps assess the effectiveness of treatment.
  • Relapse: The return of cancer after a period of improvement or remission.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer cells.
  • Intradermal Injection: A method of injecting a substance directly into the layer of skin below the surface, used for administering the WT1 mRNA DC vaccine.
  • Phase II Clinical Trial: A stage of clinical research that tests a new treatment in a larger group of people to determine its effectiveness and further evaluate its safety.

References

  1. http://clinicaltrials.eu/trial/study-on-wt1-mrna-dc-vaccine-to-prevent-relapse-in-adults-with-acute-myeloid-leukemia/